Compare RNXT & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNXT | ACCS |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 38.0M |
| IPO Year | 2021 | N/A |
| Metric | RNXT | ACCS |
|---|---|---|
| Price | $0.80 | $7.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 200.6K | 14.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,000.00 | N/A |
| Revenue This Year | $2,995.35 | $0.18 |
| Revenue Next Year | $219.61 | $7.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $6.75 |
| 52 Week High | $1.45 | $13.35 |
| Indicator | RNXT | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 42.59 |
| Support Level | $0.70 | $6.75 |
| Resistance Level | $1.07 | $8.77 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 13.46 | 53.33 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.